Research programme: antibody therapeutics - Biolojic Design
Latest Information Update: 28 Aug 2025
At a glance
- Originator Biolojic Design
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for research development in Unspecified in Israel (Parenteral)
- 13 Jul 2021 Early research in Unspecified in Israel (Parenteral) (Biolojic Design pipeline, July 2021)
- 25 Nov 2015 Biolojic Design has patents pending related to Bilojic AI based Platform